Latest research

  1. Article

    Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study

    • Francesco D’Oria
    • Costanza Falcidia
    • Luigi Gargiulo

    Introduction Real-world evidence on long-term effectiveness and safety of oral Janus kinase (JAK) inhibitors in atopic dermatitis (AD) remains limited. This study evaluated sustained long-term clinical and patient-reported disease control and safety...

    01 October 2026 Open access
  2. Article

    48-Week Real-World Atopic Dermatitis Study on Minimal Disease Activity, Associated Factors, and Agreement Between Clinician- and Patient-Reported Outcomes

    • Andrea I. Rodriguez-Sanna
    • Carmen García-Moronta
    • Trinidad Montero-Vilchez

    Introduction Atopic dermatitis (AD) requires multidimensional assessment strategies that integrate clinician and patient perspectives. Minimal disease activity (MDA) has emerged as a treatment target, although its optimal definition and real-world...

    25 September 2026 Open access
  3. Article

    Food allergen sensitization on a standardized specific-IgE core panel in the West Bank, Palestine: a retrospective analysis of 1,339 Patients, 2016–2026

    • Ibrahim Salhi
    • Ansam Mazraawi
    • Ibrahim Salhi

    Local data on food allergen sensitization in the West Bank of Palestine are scarce, and clinicians rely on allergen panels derived from dissimilar Western populations. We describe the sensitization profile of patients referred for specific-IgE...

    23 September 2026 Open access
View all research